news
Llama nanobodies could serve as new treatment for HCMV
Scientists have developed a “llama nanobody” that is capable of chasing out human cytomegalovirus (HCMV) so it is detected by the immune system.
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
news
Microcrystal electron diffraction could advance drug development
UK researchers have shown how microcrystal electron diffraction (MicroED) could obtain the structures of potential pharmaceuticals.
news
Potential COVID-19 antivirals revealed in large-scale drug analysis
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
news
Bioactivity information of one million molecules compiled
Using deep machine learning, researchers have completed the activity profiles, from chemistry to clinical level, for one million molecules.
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
news
Researchers discover class of drugs that could treat mantle cell lymphoma
A screening campaign has revealed that small molecule inhibitors of the SOX 11 oncogene are toxic to mantle cell lymphoma in vitro.
whitepaper
Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
news
Novel algorithm uses mass spec data to predict identity of molecules
A new algorithm called MolDiscovery uses mass spectrometry data from molecules to predict their identity and whether they are unknown substances.
news
Small molecule to potentially treat diabetes discovered in screening study
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
article
Covalent fragment screening in cell-based phenotypic models of disease: a collaborative approach
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
article
Targeting phosphodiesterase 3A: discovery of a promising cancer therapy
A new promising sarcoma target, phosphodiesterase 3A (PDE3A), and drugs targeting it have been identified by researchers at the University of Helsinki. Dr Katja Ivanitskiy, Dr Harri Sihto and Professor Olli Kallioniemi outline emerging evidence that indicates PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular…
article
Screening for COVID-19 drugs
With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel from the Medical Research Council (MRC) – Centre for Virus Research (CVR) at the University of Glasgow spoke with Drug Target Review’s Victoria Rees to discuss the work being done…
article
Assessing compound activity to accelerate drug discovery
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
article
Why some screening hits are a PAIN
A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated targets. Matthew Lloyd from the University of Bath explains why these hits can arise during drug discovery and how machine learning could be the answer to identifying these compounds.
article
The benefits of lab automation in life sciences
While researchers conduct their studies, constraints such as time can impact their work. Dr Ian Holland from the University of Edinburgh spoke with Drug Target Review’s Deputy Editor Victoria Rees to explain how lab automation can offer a solution to these challenges and enhance output for scientists.
